Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i>-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.
James Larkin(Trinity College Dublin), Georgina V. Long(The University of Sydney), Mario Mandalà(University of Perugia), Jacob Schachter, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Axel Hauschild(University Hospital Schleswig-Holstein), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Richard Kefford(Broad Institute), Laurent Mortier, Bijoyesh Mookerjee(Novartis (United States)), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Ran Ji(Jilin University), John M. Kirkwood(UPMC Hillman Cancer Center), Victoria Atkinson(Greenslopes Private Hospital), Paola Aimone(Novartis (Switzerland))
Cited by 11
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k